{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:17:40Z","timestamp":1778678260234,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00115-026-01961-8","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:09:12Z","timestamp":1774868952000},"page":"301-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Olanzapin-Depot in neuer Applikationsform\u00a0\u2013 Hoffnung auf das Ausbleiben von Postinjektionssyndromen","Olanzapine long acting injectable in new application form\u2014Hope for the absence of post-injection delirium\/sedation syndromes"],"prefix":"10.1007","volume":"97","author":[{"given":"Michael","family":"Paulzen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"1961_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40261-025-01507-x","volume":"46","author":"I Cherniakov","year":"2026","unstructured":"Cherniakov\u00a0I, Wagner\u00a0AM, Eshet\u00a0R et\u00a0al (2026) Safety, Tolerability, and Pharmacokinetics of Subcutaneous Extended-Release Injectable Olanzapine in Patients with Schizophrenia and Schizoaffective Disorder. Clin Drug Investig 46:307\u2013320","journal-title":"Clin Drug Investig"},{"key":"1961_CR2","doi-asserted-by":"crossref","unstructured":"Correll CU, Rohner H, Dimalta S et\u00a0al. (2026) Risperidone-ISM(\u00ae) effectiveness and tolerability in acute schizophrenia patients hospitalised due to a\u00a0relapse: results from an international, prospective, non-interventional evaluation (RESHAPE study). World J Biol Psychiatry:1-18","DOI":"10.1080\/15622975.2026.2628198"},{"key":"1961_CR3","unstructured":"DGPPN (2025) S3-Leitlinie Schizophrenie. Langfassung. Version 4.0. AWMF-Register Nr. 038 - 099. Fassung vom 15.10.2025. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/038-009. Accessed 6.3.2026"},{"key":"1961_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2147\/NDT.S5463","volume":"6","author":"R Di Lorenzo","year":"2010","unstructured":"Di Lorenzo\u00a0R, Brogli\u00a0A (2010) Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr Dis Treat 6:573\u2013581","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1961_CR5","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2215-0366(23)00288-2","volume":"10","author":"JM Kane","year":"2023","unstructured":"Kane\u00a0JM, Harary\u00a0E, Eshet\u00a0R et\u00a0al (2023) Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. Lancet Psychiatry 10:934\u2013943","journal-title":"Lancet Psychiatry"},{"key":"1961_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jamapsychiatry.2017.4711","volume":"75","author":"M Lahteenvuo","year":"2018","unstructured":"Lahteenvuo\u00a0M, Tanskanen\u00a0A, Taipale\u00a0H et\u00a0al (2018) Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. JAMA Psychiatry 75:347\u2013355","journal-title":"JAMA Psychiatry"},{"key":"1961_CR7","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s12272-013-0105-7","volume":"36","author":"EJ Park","year":"2013","unstructured":"Park\u00a0EJ, Amatya\u00a0S, Kim\u00a0MS et\u00a0al (2013) Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res 36:651\u2013659","journal-title":"Arch Pharm Res"},{"key":"1961_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00115-025-01830-w","volume":"96","author":"M Paulzen","year":"2025","unstructured":"Paulzen\u00a0M, Kuhn\u00a0J (2025) Antipsychotika abseits der Dopamin-D2-Blockade\u2013Xanomelin-Trospium als Hoffnungstr\u00e4ger? Der Nervenarzt 96:304\u2013308","journal-title":"Der Nervenarzt"},{"key":"1961_CR9","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1007\/s40120-025-00840-9","volume":"14","author":"I Perlstein","year":"2025","unstructured":"Perlstein\u00a0I, Meyer\u00a0J, Kumar\u00a0S et\u00a0al (2025) Population Pharmacokinetic-Based Strategies for Switching Patients with Schizophrenia Between Long-Acting Injectable Formulations of Risperidone: R064766 or RBP-7000 to TV-46000. Neurol Ther 14:2647\u20132667","journal-title":"Neurol Ther"},{"key":"1961_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/17425255.2025.2474126","volume":"21","author":"G Schoretsanitis","year":"2025","unstructured":"Schoretsanitis\u00a0G, Correll\u00a0CU (2025) Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophrenia. Expert Opin Drug Metab Toxicol 21:501\u2013509","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1961_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/schbul\/sbab091","volume":"48","author":"G Schoretsanitis","year":"2022","unstructured":"Schoretsanitis\u00a0G, Kane\u00a0JM, Correll\u00a0CU et\u00a0al (2022) Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data. Schizophr Bull 48:296\u2013306","journal-title":"Schizophr Bull"},{"key":"1961_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00115-024-01733-2","volume":"96","author":"W Strube","year":"2025","unstructured":"Strube\u00a0W, Wagner\u00a0E, Gartenmaier\u00a0A et\u00a0al (2025) Risiko f\u00fcr Postinjektionssyndrome nach Vergabe von Olanzapin-Depot. Der Nervenarzt 96:290\u2013293","journal-title":"Der Nervenarzt"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-01961-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-026-01961-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-01961-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:25:54Z","timestamp":1778675154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-026-01961-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1961"],"URL":"https:\/\/doi.org\/10.1007\/s00115-026-01961-8","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Die Originalversion dieses Beitrags wurde korrigiert: Die Redaktionsbox wurde nachtr\u00e4glich hinzugef\u00fcgt.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Paulzen erhielt in den letzten zwei Jahren Vortrags- und Beraterhonorare von folgen-den pharmazeutischen Unternehmen: Neuraxpharm, Lundbeck, Janssen, Otsuka, Rovi, Recordati und Idorsia. Er ist Herausgeber von PSIAC, einem internetbasierten Arzneimittelinteraktionsprogramm f\u00fcr Psychopharmakotherapie (\n                      \n                      ). Bez\u00fcglich der Erstellung des Beitrags bestanden keine Interessenkonflikte. G.\u00a0Schoretsanitis erhielt in den letzten zwei Jahren Honorare f\u00fcr Vortrags- und Beratungsleistungen von Dexcel Pharma, Lundbeck, HLS Therapeutics, OM Pharma, Saladax und Thermo Fisher Scientific. Er besitzt Aktien von Medincell und Maplight Therapeutics. Er gab an, dass bez\u00fcglich der Erstellung des Beitrags keine Interessenkonflikte bestanden.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}